NasdaqCM - Delayed Quote USD

Soleno Therapeutics, Inc. (SLNO)

37.89 +0.55 (+1.47%)
At close: April 26 at 4:00 PM EDT
35.80 -2.09 (-5.52%)
After hours: April 26 at 6:19 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Anish Bhatnagar M.D. President, CEO, COO & Director 1.06M -- 1970
Mr. James H. MacKaness Chief Financial Officer 640k -- 1964
Ms. Lauren Budesheim Vice President of People -- -- --

Soleno Therapeutics, Inc.

203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
650 213 8444 https://soleno.life
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
33

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Corporate Governance

Soleno Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Soleno Therapeutics, Inc. Earnings Call

Related Tickers

DNTH Dianthus Therapeutics, Inc.
21.50
+2.43%
 
MLTX MoonLake Immunotherapeutics
42.49
+0.57%
 
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
VERA Vera Therapeutics, Inc.
39.65
+2.48%
 
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
 
SWTX SpringWorks Therapeutics, Inc.
45.53
+3.01%
 
COGT Cogent Biosciences, Inc.
6.02
+0.17%
 
VRDN Viridian Therapeutics, Inc.
12.88
+1.42%
 
CABA Cabaletta Bio, Inc.
11.01
-9.61%
 
DYN Dyne Therapeutics, Inc.
24.73
+4.37%